Related Experiment Videos
A comparative randomized double-blind clinical trial of pivampicillin and ampicillin in lower respiratory tract
Abstract:
The efficacy and safety of pivampicillin was compared with that of ampicillin in 52 patients suffering from lower respiratory tract infections. Equimolar doses of pivampicillin (350 mg) and ampicillin (250 mg) were administered three times daily for 15 days in identical code-labeled capsules. Each patient received only one drug in a random double-blind order. Clinical as well as objective assessment showed that pivampicillin was comparatively more effective and safer than ampicillin on both the 7th and 15th day of treatment. The reduction in the volume and purulence of sputum and in cough and dyspnea was more marked with pivampicillin. The overall success rate was higher and the side effects were fewer with pivampicillin.
Insights
Pivampicillin demonstrated superior efficacy and safety compared to ampicillin for treating lower respiratory tract infections. Patients receiving pivampicillin experienced greater symptom improvement and fewer side effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Lower respiratory tract infections (LRTIs) pose a significant health burden.
- Antibiotic resistance necessitates the evaluation of alternative treatment options.
- Ampicillin is a commonly used antibiotic for bacterial infections.
Purpose of the Study:
- To compare the clinical efficacy and safety of pivampicillin versus ampicillin in patients with LRTIs.
- To evaluate objective and subjective treatment outcomes in a randomized, double-blind study.
Main Methods:
- A randomized, double-blind, controlled trial involving 52 patients with LRTIs.
- Equimolar doses of pivampicillin (350 mg) and ampicillin (250 mg) administered thrice daily for 15 days.
- Assessment of clinical improvement, sputum characteristics, and side effects.
Main Results:
- Pivampicillin showed significantly greater effectiveness than ampicillin by day 7 and day 15.
- Marked reductions in sputum volume, purulence, cough, and dyspnea were observed with pivampicillin.
- Pivampicillin exhibited a higher overall success rate and a lower incidence of adverse effects.
Conclusions:
- Pivampicillin is a more effective and safer therapeutic option for lower respiratory tract infections compared to ampicillin.
- The enhanced efficacy of pivampicillin may be attributed to improved pharmacokinetic properties.
- Further research into pivampicillin's role in respiratory infections is warranted.